Form 4: Cartesian Therapeutics Officer Exercises Stock Options

Sentiment:

SEC Form 4 Filing


Emily English, Chief Operations Officer of Cartesian Therapeutics, exercised stock options on April 15, 2025, acquiring 7,500 shares of common stock.

Summary

  • On April 15, 2025, Emily English, the Chief Operations Officer of Cartesian Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $3.3 per share.
  • Following this transaction, Ms. English directly owns 47,726 shares of common stock.
  • The exercised stock options were fully vested and exercisable.
  • These options originated from a conversion of Old Cartesian common stock options following the merger on November 13, 2023.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the actions of company executives. It's common for officers to exercise stock options as part of their compensation packages.

Key Dates

DateDescription
November 13, 2023Cartesian Therapeutics acquired Old Cartesian in a merger.
April 15, 2025Emily English exercised stock options.
April 16, 2025Date of Form 4 signature.
April 25, 2031Expiration date of stock options.

Keywords

stock options, Form 4, Cartesian Therapeutics, Emily English, insider trading, RNAC, COO

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.